Quince Therapeutics (QNCX) announced that the last patient has completed their last visit in the company’s pivotal Phase 3 NEAT clinical trial of its lead asset, encapsulated dexamethasone sodium phosphate, in patients with Ataxia-Telangiectasia. The company expects to report topline results from this study in the middle of the first quarter of 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNCX:
- Quince Therapeutics publishes summary of early-stage clinical studies of eDSP
- Promising Outlook for Quince Therapeutics: Phase 3 Study and Innovative Platform Drive Buy Recommendation
- Quince Therapeutics Reports Q3 2025 Financial Results
- Quince Therapeutics reports Q3 EPS (25c), consensus (22c)
- QNCX Upcoming Earnings Report: What to Expect?